• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮肤科部门的预先授权的行政负担和成本。

Administrative Burden and Costs of Prior Authorizations in a Dermatology Department.

机构信息

School of Medicine, University of Utah, Salt Lake City.

Department of Dermatology, Broward Health, Fort Lauderdale, Florida.

出版信息

JAMA Dermatol. 2020 Oct 1;156(10):1074-1078. doi: 10.1001/jamadermatol.2020.1852.

DOI:10.1001/jamadermatol.2020.1852
PMID:32845288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7450401/
Abstract

IMPORTANCE

Insurance companies use prior authorizations (PAs) to address inappropriate prescribing or unnecessary variations in care, most often for expensive medications. Prior authorizations negatively affect patient care and add costs and administrative burden to dermatology offices.

OBJECTIVE

To quantify the administrative burden and costs of dermatology PAs.

DESIGN, SETTING, AND PARTICIPANTS: The University of Utah Department of Dermatology employs 2 full-time and 8 part-time PA staff. In this cross-sectional study at a large academic department spanning 11 clinical locations, these staff itemized all PA-related encounters over a 30-day period in September 2016. Staff salary and benefits were publicly available. Data were analyzed between December 2018 and August 2019.

MAIN OUTCOMES AND MEASURES

Proportion of visits requiring PAs, median administrative time to finalize a PA (either approval or denial after appeal), and median cost per PA type.

RESULTS

In September 2016, 626 PAs were generated from 9512 patient encounters. Staff spent 169.7 hours directly handling PAs, costing a median of $6.72 per PA. Biologic PAs cost a median of $15.80 each and took as long as 31 business days to complete. The costliest PA equaled 106% of the associated visit's Medicare reimbursement rate. Approval rates were 99.6% for procedures, 78.9% for biologics, and 58.2% for other medications. After appeal, 5 of 23 (21.7%) previously denied PAs were subsequently approved.

CONCLUSIONS AND RELEVANCE

Prior authorizations are costly to dermatology practices and their value appears limited for some requests. Fewer unnecessary PAs and appeals might increase practice efficiency and improve patient outcomes.

摘要

重要性

保险公司使用预先授权 (PA) 来解决不当处方或护理中不必要的差异,通常是针对昂贵的药物。预先授权会对患者护理产生负面影响,并给皮肤科诊所增加成本和行政负担。

目的

量化皮肤科 PA 的行政负担和成本。

设计、设置和参与者:犹他大学皮肤科雇有 2 名全职和 8 名兼职 PA 工作人员。在这项大型学术部门的横断面研究中,跨越 11 个临床地点,这些工作人员在 2016 年 9 月的 30 天内详细列出了所有与 PA 相关的就诊情况。工作人员的薪资和福利是公开的。数据在 2018 年 12 月至 2019 年 8 月之间进行分析。

主要结果和措施

需要 PA 的就诊比例、完成 PA 的中位数行政时间(包括上诉后的批准或拒绝)以及每种 PA 类型的中位数成本。

结果

2016 年 9 月,从 9512 次患者就诊中生成了 626 个 PA。工作人员直接处理 PA 花费了 169.7 个小时,每个 PA 的中位数成本为 6.72 美元。生物制剂 PA 的中位数费用为每个 15.80 美元,完成时间最长可达 31 个工作日。最昂贵的 PA 等于相关就诊 Medicare 报销率的 106%。程序的批准率为 99.6%,生物制剂为 78.9%,其他药物为 58.2%。上诉后,23 个先前拒绝的 PA 中有 5 个(21.7%)随后获得批准。

结论和相关性

预先授权对皮肤科实践来说成本高昂,而且对于某些请求来说其价值似乎有限。减少不必要的 PA 和上诉可能会提高实践效率并改善患者的结果。

相似文献

1
Administrative Burden and Costs of Prior Authorizations in a Dermatology Department.皮肤科部门的预先授权的行政负担和成本。
JAMA Dermatol. 2020 Oct 1;156(10):1074-1078. doi: 10.1001/jamadermatol.2020.1852.
2
Evaluating the effect of prior authorizations in patients with complex dermatologic conditions.评估复杂皮肤科疾病患者的预授权的效果。
J Am Acad Dermatol. 2020 Dec;83(6):1674-1680. doi: 10.1016/j.jaad.2020.06.998. Epub 2020 Jul 2.
3
Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review.审查预先授权程序、患者结局和药学干预的影响:单中心回顾。
J Am Acad Dermatol. 2019 Dec;81(6):1308-1318. doi: 10.1016/j.jaad.2019.05.024. Epub 2019 May 16.
4
Prior authorization as a utilization management tool for elective superficial venous procedures results in high administrative cost and low efficacy in reducing utilization.择期浅表静脉手术的预授权作为一种利用管理工具,导致行政成本高,降低利用率的效果低。
J Vasc Surg Venous Lymphat Disord. 2020 May;8(3):383-389.e1. doi: 10.1016/j.jvsv.2019.10.016. Epub 2019 Dec 17.
5
Burden of Prior Authorization Requirements on Urology Practice and Patients.《论事先授权要求对泌尿科实践和患者的负担》。
Urology. 2022 Nov;169:76-83. doi: 10.1016/j.urology.2022.05.055. Epub 2022 Aug 9.
6
Impact of prior authorizations on dermatology patients: A cross-sectional analysis.预先授权对皮肤科患者的影响:一项横断面分析。
J Am Acad Dermatol. 2021 Jul;85(1):217-220. doi: 10.1016/j.jaad.2020.07.095. Epub 2020 Jul 29.
7
Prior authorizations in dermatology and impact on patient care: An updated survey of US dermatology providers and staff by the American Academy of Dermatology.皮肤病学中的预授权及其对患者护理的影响:美国皮肤病学会对美国皮肤科医生和工作人员的最新调查。
Dermatol Online J. 2021 Jan 15;27(1):13030/qt990631n9.
8
Assessing the Impact of Prior Authorizations on Dermatology Residents.评估预先授权对皮肤科住院医师的影响。
J Drugs Dermatol. 2024 Jun 1;23(6):485-488. doi: 10.36849/JDD.7617.
9
The impact of prior authorization review on orthopaedic subspecialty care: a prospective multicenter analysis.预先授权审查对矫形亚专科护理的影响:一项前瞻性多中心分析。
J Shoulder Elbow Surg. 2024 Jun;33(6):e336-e342. doi: 10.1016/j.jse.2023.10.004. Epub 2023 Nov 20.
10
Evaluation of prior authorizations in transplant recipients at an urban institution.城市医疗机构中器官移植受者的预授权评估。

引用本文的文献

1
Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey.通往皮肤科炎症性疾病专科治疗之路:治疗需求与患者就医过程
J Manag Care Spec Pharm. 2025 Feb 1;31(2):147-156. doi: 10.18553/jmcp.2025.31.2.147.
2
Analyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers.分析《安全步骤法案》对患者、医生和保险公司的收益与成本。
J Psoriasis Psoriatic Arthritis. 2024 Jul;9(3):115-120. doi: 10.1177/24755303241253203. Epub 2024 May 7.
3
Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA.评估美国特应性皮炎患者群体获取处方药的情况。
Dermatol Ther (Heidelb). 2024 Jul;14(7):1811-1821. doi: 10.1007/s13555-024-01205-0. Epub 2024 Jun 16.
4
Discordance Between Inflammatory Bowel Disease Specialists and Insurance Authorization Denials-A Survey of Specific Inflammatory Bowel Disease Treatment Scenarios.炎症性肠病专家与保险授权拒绝之间的不一致——特定炎症性肠病治疗方案的调查
Crohns Colitis 360. 2023 Dec 30;6(1):otad082. doi: 10.1093/crocol/otad082. eCollection 2024 Jan.
5
The Impact of Insurance Restrictions in Newly Diagnosed Individuals With Multiple Sclerosis.保险限制对新诊断的多发性硬化症患者的影响。
Int J MS Care. 2024 Jan-Feb;26(1):17-21. doi: 10.7224/1537-2073.2022-069. Epub 2024 Jan 5.
6
Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel.糖尿病药物自动与手动预先授权:一项来自以色列的回顾性研究。
Digit Health. 2023 Sep 28;9:20552076231203889. doi: 10.1177/20552076231203889. eCollection 2023 Jan-Dec.
7
Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease.生物治疗剂量升级与炎症性肠病患者疾病活动相关的保险批准延迟。
Dig Dis Sci. 2023 Dec;68(12):4331-4338. doi: 10.1007/s10620-023-08098-7. Epub 2023 Sep 19.
8
Medicare Opt-Out Trends Among Dermatologists May Reflect Systemic Health Policy: Cross-sectional Analysis.皮肤科医生中医疗保险选择退出趋势可能反映系统性健康政策:横断面分析
JMIR Dermatol. 2022 Nov 8;5(4):e42345. doi: 10.2196/42345.
9
Impact of pharmacist alternative therapy interventions in a pediatric Medicaid population.药师替代疗法干预对小儿医疗补助人群的影响。
J Manag Care Spec Pharm. 2023 Jul;29(7):835-841. doi: 10.18553/jmcp.2023.29.7.835.
10
Is Time Spent on Prior Authorizations Associated With Approval?花在预先授权上的时间与批准有关吗?
J Nurse Pract. 2023 Feb;19(2). doi: 10.1016/j.nurpra.2022.10.008. Epub 2022 Nov 10.